Landos Biopharma Inc (LABP) 銘柄情報

i did the same the other day, at 61 average in after market..will buy again on the next correction, which will be very soon..

LABP...HERE WE GO...60S

BOOM...60C BID ...GOING TO A DOLLA

lmao...gapping...another lesson taught

Boom breaking 50s. Next dollar runner

LABP READY TO RUMBLE AGAIN

LABP nice close and ready to pop next week

LABP one more try here on the 46c break

LABP heres a 46c bid....key break

LABP lets see that all important 46c break here

hopped back out for a…

…

small profit before the dump but im watching it.

this is a bouncy one for sure.

lmao...38c to 58c keep watching the magic

Doh! LMAO

grabbed a few 41s on that sell off...holding the 50 day...only one target and that would be the 100 day...chart is not bullish

a/h trading looking good. I….

…

guess i will be on this run by myself, the board got quiet.

here we goooo!!!

congrats. i got in on the dip.

SOLD ON THAT PUSH

yeah, but it is breaking the other way now....

WHAMO....30 MILLION FLOAT

MONSTER

LABP HERES THE 46 BREAK...MONSTER

LABP 43c ask stack on a good 60 min...

LABP 42s getting smashed

LABP getting jiggy...46c break sends it

Another 30% today, betting news gonna drop, lotta volume

$LABP in +23.5% Uptrend, growing for three consecutive days on December 13, 2022. View odds for this and other indicators: https://t.co/2GkAz2CU82 #LandosBiopharma pic.twitter.com/XIfQQ40Ry4— Tickeron (@Tickeron) December 14, 2022

ER being released Aug 11 after market close…

Thanks….

Landos Biopharma Reports Positive Top-Line Results From NX-13 Phase 1b Trial
August 03 2022 - 08:00AM
GlobeNewswire Inc.
Alert
Print
Share On Facebook

Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced positive top-line results from its Phase 1b clinical trial of NX-13, a novel, oral, NLRX1 agonist in development for the treatment of ulcerative colitis (UC) as a once-daily oral therapy. The data showed that NX-13 was well tolerated following evaluation of multiple doses over four weeks compared with a placebo.
Based on these results, the Company plans to initiate a Phase 2 clinical trial to evaluate the safety, efficacy, and optimal dosing of NX-13 in UC patients.

“We are pleased to announce the successful completion of our Phase 1b trial of NX-13, which marks an important milestone for Landos,” said Gregory Oakes, President and CEO of Landos. “NX-13 showed a favorable safety and tolerability profile in UC patients across a range of doses. While the study was shorter in duration than standard induction trials and not powered for efficacy, there was an indication of promising signals of clinical improvement as soon as two weeks in patients’ symptoms and four weeks by endoscopy in exploratory endpoints. This early signal, as well as the data from a long-term toxicology study, support the potential of NX-13 as an important new treatment for UC. Landos is eager to advance the learnings from this Phase 1b trial through further analysis of its clinical, pharmacokinetic, and pharmacodynamic data and an appropriately designed proof of concept trial. To this end, Landos plans to advance this product candidate into a Phase 2 clinical trial.”

The Phase 1b study was a randomized, double-blind, placebo-controlled study to evaluate safety and pharmacokinetics of NX-13 at multiple dose levels, which was orally administered once-daily over four weeks. 38 adult patients with active UC with a total Mayo score between four and ten were enrolled in the study. Dose arms of 250mg immediate release (IR), 500mg IR, and 500mg modified release (MR) were tested, with each arm containing 11 participants. Five participants received a placebo.

Across the four cohorts, no serious adverse events (SAEs) were reported, consistent with earlier studies in healthy volunteers and preclinical models.

“The continued development of NX-13 is one of several important initiatives underway at Landos,” continued Mr. Oakes. “Since joining the Company in June, I have been working closely with the Board of Directors to review the business and finalize the development of a focused plan to advance the pipeline and optimize successful outcomes for our three clinical-stage programs. There is positive momentum underway at Landos, and we are optimistic about the potential for NX-13 for patients suffering from UC. We look forward to providing a comprehensive update on our clinical development plans later this year.”

About NX-13
NX-13 is a novel, gut-restricted, orally active, small molecule therapeutic candidate for the treatment of UC. NX-13 targets NLRX1, a mitochondria-associated receptor with the ability to modulate immune responses. By activating the NLRX1 pathway, NX-13 is designed to increase oxidative phosphorylation in immune cells, reduce differentiation of effector CD4-positive T cells, and decrease production of inflammatory cytokines in the gastrointestinal tract.

About Landos Biopharma
Landos Biopharma is a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapeutics for patients with autoimmune diseases. We believe we were the first to identify and target LANCL2, NLRX1 and PLXDC2, which are immunometabolic pathways or targets. We have identified seven novel immunometabolic pathways or targets based on predictions of immunometabolic function using a proprietary advanced artificial intelligence-based integrated computational and experimental precision medicine platform. Our near-term focus is on our clinical-stage programs including omilancor for the treatment of UC, NX-13 for the treatment of UC, and LABP-104 for the potential treatment of systemic lupus erythematosus and rheumatoid arthritis.

For more information, please visit www.landosbiopharma.com.

Cautionary Note on Forward-Looking Statements

O/S. 40 million
Float 11.25 million
Insiders 10 million
Institutions 26 million
Short shares 115,000

These are the facts as I know them. I am not pumping .
News on trial progress due mid year. Good news and the price goes up. Bad trial news will hurt financially due to low daily volume.
They need to reign in spending as 70 million doesn’t go far nowadays.

GL, May all your trades work out….

How about the float or As or OS. Good pump

Great expansive pipeline, 70 million million in the bank, well connected experienced management and all for 70 measly Pennie’s a share.

LANDOSBIOPHARMA.COM for more info…